Granules India Ltd vs Orchid Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 699.25 as of 30 Apr 15:30 . The P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 yearsThe P/E Ratio of Orchid Pharma Ltd changed from 33.9 on March 2023 to 39.5 on March 2025 . This represents a CAGR of 5.23% over 3 years The Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 yearsThe Market Cap of Orchid Pharma Ltd changed from ₹ 10061 crore on March 2021 to ₹ 3940 crore on March 2025 . This represents a CAGR of -17.10% over 5 years The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The revenue of Orchid Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 212.88 crore. This represent the decline of -100% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The ebitda of Orchid Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0.06 crore. This represent the decline of -100% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The net profit of Orchid Pharma Ltd changed from ₹ 28.27 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Orchid Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Orchid Pharma Ltd

Orchid Pharma Limited, is a vertically integrated pharmaceutical company with established research, manufacturing and marketing capabilities across multi-therapeutic domains.
Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India.
The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company has a portfolio of antibiotics, and veterinary products.
Antibiotics are life-saving drugs used to ght infections.
Different classes of antibiotics include Beta-lactam, Macrolide, Fluoroquinolone, Imidazoleetc.

FAQs for the comparison of Granules India Ltd and Orchid Pharma Ltd

Which company has a larger market capitalization, Granules India Ltd or Orchid Pharma Ltd?

Market cap of Granules India Ltd is 17,327 Cr while Market cap of Orchid Pharma Ltd is 3,187 Cr

What are the key factors driving the stock performance of Granules India Ltd and Orchid Pharma Ltd?

The stock performance of Granules India Ltd and Orchid Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Orchid Pharma Ltd?

As of May 4, 2026, the Granules India Ltd stock price is INR ₹699.25. On the other hand, Orchid Pharma Ltd stock price is INR ₹628.5.

How do dividend payouts of Granules India Ltd and Orchid Pharma Ltd compare?

To compare the dividend payouts of Granules India Ltd and Orchid Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.